Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 1878-1888

  Cassidy, Shawn M ^a   Strobel, Frank W ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOSOME; NYSTATIN;

ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0031928702     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.1878     Document Type: Article

References (39)

1. Budavari, S. (ed.). 1989. The Merck index, 11th ed. Merck and Co. Inc., Rahway, N.J.
2. Cushley, R. J., W. D. Treleaven, Y. I. Parmar, R. S. Chana, and D. B. Fenske. 1987. Surface diffusion in human serum lipoproteins. Biochem. Biophys. Res. Commun. 146:1139-1145.
3. 14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay. Biochim. Biophys. Acta 712:444-452.
4. Damen, J., J. Regts, and G. Scherphof. 1981. Transfer and exchange of phospholipid between small unilamcllar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim. Biophys. Acta 665:538-545.
5. 14C]dimyristoylphosphatidylcholine from liposomes to subfractions of human plasma high density lipoproteins as resolved by isoelectric focusing. FEBS Lett. 105:115-119.
6. Davis, R. A., and J. E. Vance. 1996. Structure, assembly and secretion of lipoproteins, p. 473-493. In D. E. Vance and J. E. Vance (ed.), Biochemistry of lipids, lipoproteins and membranes. Elsevier, New York, N.Y.
7. Davis, R. A. 1991. Lipoprotein structure and secretion, p. 403-426. In D. E. Vance and J. E. Vance (ed.), Biochemistry of lipids, lipoproteins and membranes. Elsevier, New York, N.Y.
8. Eisenberg, S. 1984. High density lipoprotein metabolism. J. Lipid Res. 25: 1017-1058.
9. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:211-228.
10. Fielding, P. E., and C. J. Fielding. 1996. Dynamics of lipoprotein transport in the human circulatory system, p. 495-516. In D. E. Vance and J. E. Vance (ed.), Biochemistry of lipids, lipoproteins and membranes. Elsevier, New York, N.Y.
11. Hatch, F. T., and R. S. Lees. 1968. Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6:1-68.
12. Havel, R. J., and J. P. Kane. 1995. Introduction: structure and metabolism of plasma lipoproteins, p. 1129-1138. In C. R. Scriver. A. L. Beaudet, W. S. Sly, and D. Valle (ed.), The metabolic and molecular basis of inherited disease, vol. 2. McGraw-Hill Book Co., New York, N.Y.
13. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
14. Jusko, W. J., and M. Gretch. 1976. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab. Rev. 5:43-140.
15. Lopez-Berestein, G. 1988. Liposomes as carriers of antifungal drugs. Ann. N. Y. Acad. Sci. 544:590-597.
16. Lopez-Berestein, G., V. Fainstein, R. L. Hopfer, K. Mehta, M. P. Sullivan, M. Keating, M. G. Rosenblum, R. Mehta, M. Luna, E. M. Hersh, J. Reuben, R. L. Juliano, and G. P. Bodey. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151:704-710.
17. Lopez-Berestein, G., M. Rosenblum, and R. Mehta. 1984. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery 1:199-205.
18. Lopez-Berestein, G., R. L. Hopfer, R. T. Mehta, K. Mehta, E. M. Hersh, and R. L. Juliano. 1984. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J. Infect. Dis. 150:278-283.
19. Lopez-Berestein, G., R. T. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E. M. Hersh, and R. T. Juliano. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147:939-945.
20. Mehta, R. T., and G. Lopez-Berestein. 1989. Effect of liposome encapsulation on toxicity and antifungal activity on polyene antibiotics, p. 263-273. In G. Lopez-Berestein and I. J. Fidler (ed.), Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc., New York, N.Y.
21. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
22. Mehta, R. T., G. Lopez-Berestein, R. L. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta 770:230-234.
23. Rios, A., M. Rosenblum, G. Crofoot, R. P. Lenk, A. Hayman, and G. Lopez-Berestein. 1993. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J. Infect. Dis. 168:153-154.
24. Rowland, M. 1980. Plasma protein binding and therapeutic monitoring. Ther. Drug Monit. 2:29-37.
25. Schneider, W. J. 1996. Removal of lipoproteins from plasma, p. 517-541. In D. E. Vance and J. E. Vance (ed.), Biochemistry of lipids, lipoproteins and membranes. Elsevier, New York, N.Y.
26. Surewicz, W. K., R. M. Epand, H. J. Pownall, and S. W. Hui. 1986. Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids. J. Biol. Chem. 261:16191-16197.
27. Wasan, E. K., D. L. Reimer, and M. B. Bally. 1996. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J. Pharm. Sci. 85:427-433.
28. Wasan, K. M., M. Ramaswamy, S. M. Cassidy, M. Kazemi, F. W. Strobel, and R. L. Thies. 1997. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother. 41: 1871-1875.
29. Wasan, K. M., P. H. Pritchard, M. Ramaswamy, W. Wong, E. M. Donnachie, and L. J. Brunner. 1997. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 14:1614-1621.
30. Wasan, K. M., S. M. Cassidy, F. W. Strobel, and S. Ng. A comparison of step-gradient and sequential ultracentrifugation in determining the lipoprotein distribution of nystatin incorporated into lipid-based vesicles of heterogeneous sizes. Submitted for publication.
31. Wasan, K. M., and J. S. Conklin. 1997. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24:78-80.
32. Wasan, K. M., and G. Lopez-Berestein. 1997. Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur. J. Clin. Microbiol. Infect. Dis. 16:81-92.
33. Wasan, K. M., and R. E. Morton. 1996. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm. Res. 13:462-468.
34. Wasan, K. M. 1996. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Methods 36:1-11.
35. Wasan, K. M., and R. Perez-Soler. 1995. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J. Pharm. Sci. 84:1094-1100.
36. Wasan, K. M., M. G. Rosenblum, L. Cheung, and G. Lopez-Berestein. 1994. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:223-227.
37. Wasan, K. M., G. A. Brazeau, A. Keyhani, A. C. Hayman, and G. Lopez-Berestein. 1993. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246-250.
38. Wasan, K. M., K. Vadiei, G. Lopez-Berestein, and D. R. Luke. 1990. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 161:562-566.
39. Zini, R., P. Riant, J. Barre, and J. P. Tillement. 1986. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (parts 1 and 2). Clin. Pharmacokinet. 19:147-159, 218-229.